Deborah H. Yellin
Overview
Deborah H. Yellin is a partner in Crowell & Moring's Washington, D.C. office. She focuses her practice on U.S. Patent and Trademark Office post-grant proceedings, intellectual property portfolio management, patent procurement, counseling and district court litigation.
Career & Education
- Tufts University, B.S., magna cum laude, 1996
- The George Washington University Law School, J.D., 2000
- The George Washington University School of Medicine, M.P.H., 2000
- District of Columbia
- Virginia
- U.S. Patent and Trademark Office (USPTO)
- Supreme Court of the United States
- U.S. Court of Appeals for the Federal Circuit
- U.S. Court of Appeals for the Fourth Circuit
Professional Activities and Memberships
- Patent Trial and Appeal Board (PTAB) Bar Association
- American Intellectual Property Law Association
- American Chemical Society
- Virginia Bar Association
- Patent Trial and Appeal Board (PTAB) Bar Association
- Japanese
Deborah's Insights
Client Alert | 2 min read | 01.11.24
Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen
On January 10, 2024, the United States Patent and Trademark Office (USPTO) published Guidelines for assessing enablement after the Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al. The Guidelines inform Examiners and the public on the Office’s implementation of the Amgen opinion. In sum, the Guidelines maintain the status quo.
Press Coverage | 01.04.24
Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm
Press Coverage | 12.18.23
Publication | 05.24.23
Representative Matters
- Apotex, Inc., et al. v. Amgen, Inc. Representing petitioner Apotex in inter partes review before the PTAB related to anti-cancer drugs, securing victory for Apotex at the PTAB.
- Apotex, Inc., et al. v. Novartis AG, et al. Representing petitioner Apotex in inter partes review before the PTAB related to a multiple sclerosis drug, securing victory for Apotex at the PTAB and in the resulting appeal at the Federal Circuit.
- Moderna v. CureVac, representing patent owner CureVac in inter partes review before the PTAB relating to purification of RNA.
- LifeNet Health v. Life Cell Corp., No. 2:13-cv-00486 (E.D. Virginia): Represented plaintiff LifeNet in patent-infringement action involving soft-tissue grafts. Jury awarded LifeNet over $34 million; decision affirmed on appeal.
- Takeda Pharmaceutical Co., Ltd. et al. v. Handa Pharmaceuticals, LLC and Par Pharmaceutical, Inc., No. 3:11-840 (N.D. Cal.), and Par Pharmaceutical, Inc. and Handa Pharmaceuticals, LLC v. Takeda Pharmaceutical Co., Ltd. et al., No. 5:13-1927 (N.D. Cal.). Represented Handa and Par in patent infringement cases concerning Par's ANDA for a generic version of Dexilant® (dexlansoprazole).
- E.I. du Pont de Nemours and Company v. Kolon Industries, Inc., et al., No. 3:09-cv-58 (E.D. Virginia). Represented plaintiff DuPont in case alleging misappropriation of over 100 trade secrets relating to KEVLAR® fiber technology in one of the largest trade secret misappropriation cases in the United States. Obtained a $919 million verdict against Kolon for the theft of KEVLAR® technology after a seven-week jury trial held in Richmond, Virginia.
Deborah's Insights
Client Alert | 2 min read | 01.11.24
Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen
On January 10, 2024, the United States Patent and Trademark Office (USPTO) published Guidelines for assessing enablement after the Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al. The Guidelines inform Examiners and the public on the Office’s implementation of the Amgen opinion. In sum, the Guidelines maintain the status quo.
Press Coverage | 01.04.24
Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm
Press Coverage | 12.18.23
Publication | 05.24.23
Deborah's Insights
Client Alert | 2 min read | 01.11.24
Enabling Practitioners: USPTO Issues Guidelines for Assessing Enablement Post-Amgen
On January 10, 2024, the United States Patent and Trademark Office (USPTO) published Guidelines for assessing enablement after the Supreme Court’s recent decision in Amgen Inc. et al. v. Sanofi et al. The Guidelines inform Examiners and the public on the Office’s implementation of the Amgen opinion. In sum, the Guidelines maintain the status quo.
Press Coverage | 01.04.24
Crowell IP Powerhouse Rea Leaves Legacy Of Women Leaders At Firm
Press Coverage | 12.18.23
Publication | 05.24.23